Iroko Pharmaceuticals, LLC

Axsome Therapeutics, Inc. , New York, NY, has become the latest sponsor entranced by the analgesic potential of meloxicam to stumble on the BCS class II drug’s virtual insolubility. Like others before

Pfizer Inc. has celebrated the results of its PRECISION clinical study, which found that the drug giant's erstwhile blockbuster Celebrex (celecoxib) poses no more of a cardiovascular risk than do

CEOs And Presidents David Meek takes the helm at Ipsen July 18 as its new CEO. He had headed oncology programs at Baxalta Inc., now part of Shire PLC following the June close of its acquisit

A survey suggests drug firms need to better inform consumers about nonsteroidal anti-inflammatory drugs' potential risks and could tap into a sales growth driver in a sizeable group of consumers who a